Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ALVR AlloVir, Inc. daily Stock Chart
ALVR [NASD]
AlloVir, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.44 Insider Own36.40% Shs Outstand57.34M Perf Week34.33%
Market Cap1.70B Forward P/E- EPS next Y-1.47 Insider Trans16.22% Shs Float23.45M Perf Month-18.06%
Income-30.70M PEG- EPS next Q-0.30 Inst Own- Short Float0.57% Perf Quarter-
Sales0.00M P/S- EPS this Y-192.30% Inst Trans- Short Ratio0.23 Perf Half Y-
Book/sh- P/B- EPS next Y-2.10% ROA- Target Price46.50 Perf Year-
Cash/sh2.02 P/C14.65 EPS next 5Y- ROE- 52W Range18.15 - 45.28 Perf YTD16.50%
Dividend- P/FCF- EPS past 5Y- ROI51.80% 52W High-29.56% Beta-
Dividend %- Quick Ratio15.30 Sales past 5Y- Gross Margin- 52W Low75.73% ATR3.67
Employees21 Current Ratio15.30 Sales Q/Q- Oper. Margin- RSI (14)- Volatility14.85% 13.18%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.89 Prev Close29.58
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume577.89K Price31.89
Recom1.70 SMA2016.63% SMA505.45% SMA2005.45% Volume485,032 Change7.83%
Aug-24-20Initiated SVB Leerink Outperform $41
Aug-24-20Initiated Morgan Stanley Overweight $49
Aug-24-20Initiated JP Morgan Overweight $50
Sep-21-20 06:14AM  
AlloVir Gains 14% On FDA Trial Nod For Covid-19 Therapy
SmarterAnalyst +7.83%
Sep-17-20 09:49AM  
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 Patients
GlobeNewswire
Sep-08-20 04:15PM  
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
GlobeNewswire -6.74%
Sep-02-20 07:30AM  
AlloVir Reports Second Quarter 2020 Financial Results
GlobeNewswire
Aug-25-20 07:30AM  
AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
GlobeNewswire
Aug-03-20 04:30PM  
AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
GlobeNewswire
Jul-30-20 08:53AM  
AlloVir prices upsized IPO at $17, to be valued at over $1 billion
MarketWatch
07:32AM  
AlloVir Announces Pricing of Upsized Initial Public Offering
GlobeNewswire
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jovan-Embiricos MoranaDirectorAug 03Buy17.002,900,00049,300,0002,800,000Aug 06 06:06 AM
VAN BEEK JEROEN BChief Commercial OfficerAug 03Buy17.003,00051,000524,640Aug 05 09:55 PM
Brainard DianaDirectorAug 03Buy17.006,300107,1006,300Aug 05 09:42 PM
Atillasoy ErcemSee RemarksAug 03Buy17.003,50059,50078,500Aug 05 09:39 PM
open in yahoo | open in reuters | open in google